TG Therapeutics Posts 35c Q3 EPS as BRIUMVI Momentum Builds
TGTX has more than doubled off its 52-week low of $26.76.
Summary
TG Therapeutics reported third-quarter EPS of 35 cents, per Dow Jones, on third-quarter revenue of $259.9M. That follows a strong second quarter in which BRIUMVI U.S. revenue hit $227.7M, up 64% year over year, and management raised full-year guidance to roughly $950M. The company has now raised its 2026 revenue guidance again, targeting over $1.0B. It also carries a $300M expanded buyback and $500M of non-dilutive capital secured earlier this year, so profitability at this level is a meaningful step for a commercial-stage biotech.
At the time of this announcement, TGTX was trading at $58.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $26.76 to $63.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.